PT. SANDIPALA ARTHAPUTRA & 2 Ors v STMICROELECTRONICS ASIA PACIFIC PTE LTD & 2 Ors

Case Details

• Citation: [2018] SGCA 17
• Court: Court of Appeal of the Republic of Singapore
• Decision Date: 6 April 2018
• Coram: Sundaresh Menon CJ, Judith Prakash JA, and Steven Chong JA
• Case Number: Civil Appeal No 106 of 2017
• Hearing Date(s): 5 February 2018
• Appellants: PT Sandipala Arthaputra; Paulus Tannos; Catherine Tannos
• Respondents: ST Microelectronics Asia Pacific Pte Ltd; Oxel Systems Pte Ltd; Vincent Pierre, Luc, Cousin
• Counsel for Appellants: Prem Gurbani, Govintharasah s/o Ramanathan, and Shafkat Fahmid Sifat (Gurbani & Co LLC)
• Counsel for First and Third Respondents: Ong Tun Wei Danny, Yam Wern Jhien, Danitza Hon Cai Xia, Gan Eng Tong, and Teo Li Ping, Annabelle (Rajah & Tann Singapore LLP)
• Counsel for Second Respondent: Davinder Singh SC, Jaikanth Shankar, Timothy Lin, Jaspreet Singh, Tan Ruo Yu, and Low Wu Yang (Drew and Napier LLC)
• Practice Areas: Tort (Conspiracy); Contract (Breach of Supply Contract); Company Law (Directors’ Liability)
• Judgment Length: 22,575 words; approximately 75 pages

Summary

The decision in PT Sandipala Arthaputra & 2 Ors v STMicroelectronics Asia Pacific Pte Ltd & 2 Ors represents a landmark clarification by the Singapore Court of Appeal regarding the personal liability of directors for the contractual breaches of their companies. The dispute originated from a massive commercial failure involving the supply of 100 million microchips intended for Indonesia’s national electronic identification card project (the "e-KTP Project"). When the chips supplied by Oxel Systems Pte Ltd ("Oxel") were found to be incompatible with the required operating system, the purchaser, PT Sandipala Arthaputra ("Sandipala"), alleged breach of contract and misrepresentation. Oxel counterclaimed for breach of contract and, crucially, sued Sandipala’s directors—Mr. Paulus Tannos and Ms. Catherine Tannos—personally for the tort of conspiracy by unlawful means.

The High Court had originally dismissed Sandipala’s claims and allowed Oxel’s counterclaims, finding the directors personally liable for conspiracy. The central doctrinal question before the Court of Appeal was whether a director, acting as the "alter ego" or the directing mind and will of a company, can be held personally liable in tort for procuring or conspiring to cause the company’s own breach of contract. This required the Court to reconcile the separate legal personality of the corporation with the reality that companies can only act through human agents.

The Court of Appeal, in a judgment delivered by Steven Chong JA, restated and refined the Said v Butt principle. The Court held that a director is generally immune from tortious liability for their company's breach of contract if they act bona fide within the scope of their authority. Crucially, the Court clarified that "bona fide" in this context does not necessarily mean "in the best interests of the company" in a fiduciary sense, but rather that the director’s acts must not constitute a breach of their personal legal duties to the company. This decision provides a robust shield for directors against "unwarranted legal actions" arising from commercial decisions that lead to contractual defaults.

Ultimately, while the Court of Appeal upheld the findings of contractual breach against Sandipala, it allowed the appeal in relation to the unlawful means conspiracy claim against the directors. The Court found that there was no evidence the Tannoses had breached any personal duties to Sandipala in directing the company to stop taking delivery of the chips. Consequently, the personal liability imposed on the directors by the High Court was set aside, reinforcing the boundary between corporate contractual obligations and personal tortious liability.

Timeline of Events

1. 20 May 2011: Proof-of-concept testing conducted at Sandipala’s factory in Indonesia for the e-KTP Project. The parties later disputed whether ST chips or NXP chips were the subject of this evaluation.
2. 21 June 2011: Further testing and evaluation phases for the Indonesian government tender process.
3. 4 August 2011: Internal communications and negotiations regarding the technical specifications of the chips to be supplied.
4. 9 November 2011: The Supply Contract is concluded between Sandipala and Oxel for the supply of 100 million microchips at a unit price of US$0.60 (total value US$60 million).
5. 14 November 2011: Sandipala makes a down payment of US$1.2 million to Oxel for the first batch of chips.
6. 10 January 2012: Disputes arise regarding the compatibility of the ST chips with the "PAC" operating system provided by Oxel.
7. 13 January 2012: Sandipala expresses concerns that the chips supplied are not identical to the "Tender Evaluation Chips."
8. 19 January 2012: Oxel maintains that the chips are compliant with the Supply Contract specifications.
9. 22 January 2012: Sandipala ceases taking delivery of further batches of chips, leading to allegations of breach by Oxel.
10. 8 February 2012: Formal notices of default and dispute are exchanged between the parties.
11. 28 June 2012: Sandipala commences Suit No 518 of 2012 against ST-AP, Oxel, and Mr. Cousin.
12. 5 April 2017: The High Court delivers judgment in [2017] SGHC 102, dismissing Sandipala’s claims and allowing Oxel’s counterclaims.
13. 12 January 2018: Related proceedings regarding the assessment of damages and costs in the High Court.
14. 5 February 2018: Substantive hearing of the appeal before the Court of Appeal.
15. 6 April 2018: The Court of Appeal delivers its judgment in [2018] SGCA 17.

What Were the Facts of This Case?

The litigation arose from the "e-KTP Project," a massive initiative by the Indonesian government to issue electronic identification cards to its citizens. The project required the production of approximately 172 million cards. PT Sandipala Arthaputra ("Sandipala"), an Indonesian company, was part of a consortium led by Perum Percetakan Negara ("PNRI") that won the tender for the project. Sandipala’s specific role was the production and personalisation of the physical cards, which required the embedding of microchips encoded with a specific operating system.

The supply chain involved three main entities. ST Microelectronics Asia Pacific Pte Ltd ("ST-AP") manufactured the hardware (the microchips). Oxel Systems Pte Ltd ("Oxel") provided the software operating system, known as "PAC," which was to be encoded onto the ST chips. Vincent Pierre Luc Cousin was a director of Oxel and an employee of ST-AP. On 9 November 2011, Sandipala and Oxel entered into a "Supply Contract" for 100 million microchips at a price of US$0.60 per chip, totaling US$60 million. The contract was structured around quarterly deliveries, with Sandipala required to pay a 20% down payment for each batch. Sandipala paid the first down payment of US$1.2 million on 14 November 2011.

A critical factual dispute centered on the "Tender Evaluation Chips." During the tender process in May 2011, proof-of-concept testing was conducted. Sandipala alleged that the chips tested and approved by the Indonesian government were a specific type of ST chip that worked seamlessly with the PAC operating system. They contended that Oxel and ST-AP had expressly or impliedly promised to supply chips "identical to the Tender Evaluation Chips." However, when deliveries commenced, Sandipala claimed the chips were incompatible with the project's technical requirements, leading to high failure rates during personalisation.

The respondents (Oxel and ST-AP) countered that the chips tested in May 2011 were actually NXP chips, not ST chips, because the ST chips were not yet ready for evaluation at that stage. They argued that Sandipala was fully aware of the specifications of the ST chips it was ordering and that the Supply Contract did not contain a term requiring the chips to be "identical" to any evaluation samples. The High Court Judge accepted the respondents' version of events, finding that Sandipala had failed to prove the existence of the alleged "Tender Evaluation Chips" as a contractual benchmark.

As the project progressed, Sandipala faced significant pressure from the Indonesian government and the PNRI consortium due to delays. Sandipala eventually stopped taking delivery of the chips and failed to make subsequent down payments. Oxel treated this as a repudiatory breach of the Supply Contract. In the ensuing litigation, Oxel not only sought damages for breach of contract from Sandipala but also brought a counterclaim against Sandipala’s directors, Paulus and Catherine Tannos. Oxel alleged that the Tannoses had conspired with Sandipala to injure Oxel by unlawful means—specifically by causing Sandipala to breach the Supply Contract and by making false police reports in Indonesia against Oxel’s personnel.

The High Court found in favor of Oxel on almost all counts. It held that Sandipala was in breach of the Supply Contract and that the Tannoses were personally liable for conspiracy by unlawful means. The Judge found that the Tannoses had the requisite "predominant purpose" to injure Oxel and had used the company’s breach of contract as the "unlawful means" to achieve this end. This finding of personal liability against the directors, despite them acting in their capacity as the company's controllers, formed the primary legal battleground on appeal.

What Were the Key Legal Issues?

The appeal necessitated the resolution of several complex legal issues, ranging from factual findings on contractual terms to fundamental principles of tort and company law. The Court of Appeal identified the following as the primary issues:

• Contractual Terms and Breach: Whether the Supply Contract contained an express or implied term that the chips supplied must be "identical to the Tender Evaluation Chips." This involved a review of the High Court’s findings on the events of May 2011 and the interpretation of the one-page Supply Contract.
• Fraudulent Misrepresentation: Whether ST-AP or Oxel had made fraudulent misrepresentations regarding the exclusive distributorship of the chips or their compatibility, which induced Sandipala to enter the contract.
• The Scope of Directors' Personal Liability: This was the "interesting issue" identified by the Court at [5]. It required a determination of the proper legal basis for imposing tortious liability on directors for their company’s breach of contract. Specifically, does the Said v Butt principle apply to the tort of unlawful means conspiracy?
• The "Bona Fide" Requirement: What is the correct interpretation of the requirement that a director must act "bona fide within the scope of his authority" to enjoy immunity from liability for the company's breach? Does this require the director to act in the best interests of the company, or merely to refrain from breaching personal duties?
• Unlawful Means Conspiracy: Whether the elements of the tort were satisfied, particularly whether a breach of contract by a company (procured by its directors) can constitute the "unlawful means" required to hold the directors personally liable.
• Duty to Mitigate: Whether Oxel had failed to mitigate its losses by not reselling the chips that Sandipala refused to accept.

How Did the Court Analyse the Issues?

The Court of Appeal’s analysis began with the contractual dispute. It affirmed the High Court’s finding that there was no term in the Supply Contract requiring the chips to be "identical to the Tender Evaluation Chips." The Court noted that Sandipala’s case on this point was "evidentially thin" and contradicted by the contemporaneous documents. The Court also dismissed the claims of fraudulent misrepresentation, agreeing with the Judge that Sandipala had not relied on any alleged representations regarding exclusive distributorship when entering the contract.

The Restatement of the Said v Butt Principle

The core of the judgment is the Court’s exhaustive analysis of a director’s liability for a company’s torts and breaches of contract. The Court started with the foundational principle in Said v Butt [1920] 2 KB 497. In that case, McCardie J held that:

"if a servant acting bona fide within the scope of his authority procures or causes the breach of a contract between his employer and a third person, he does not thereby become liable to an action of tort at the suit of the person whose contract has thereby been broken." (at [53])

The Court of Appeal observed that this principle is essential to maintain the efficacy of the corporate form. If every director who decided that a company should breach a contract (perhaps for sound commercial reasons) was personally liable for inducing that breach, it would "undermine the very basis of the limited liability of companies" (at [54]).

Application to Unlawful Means Conspiracy

The Court then addressed whether this immunity extends to the tort of unlawful means conspiracy. The High Court had found the Tannoses liable because they had "conspired" with Sandipala to cause the breach. The Court of Appeal disagreed with this approach. It held that the policy reasons underlying Said v Butt apply with equal force to conspiracy. If a director is immune from the tort of inducing a breach of contract, they should not be stripped of that immunity simply because the claim is framed as a conspiracy between the director and the company to cause that same breach.

The Court cited the English Court of Appeal in Sabaf SpA v MFI Furniture Centres Ltd [2002] EWCA Civ 976 and the High Court of Australia in O’Brien v Dawson (1942) 66 CLR 18 to support the view that a director and a company, acting as one mind, cannot be said to "conspire" in a way that creates personal liability for the director for the company's own contractual default.

Defining "Bona Fide"

A significant portion of the judgment was dedicated to clarifying the "bona fide" requirement. Previous cases, such as Otech Pakistan Pvt Ltd v Clough Engineering Ltd and Another [2005] SGHC 98, had suggested that a director only acts "bona fide" if they act in the best interests of the company. The Court of Appeal rejected this narrow fiduciary-based interpretation. It held at [62]:

"the Said v Butt principle should be interpreted to exempt directors from personal liability for the contractual breaches of their company (whether through the tort of inducement of breach of contract or unlawful means conspiracy) if their acts, in their capacity as directors, are not in themselves in breach of any fiduciary or other personal legal duties owed to the company."

The Court reasoned that whether a director has breached a duty to the company is a matter between the director and the company. A third-party contractant should not be able to "bootstrap" a director’s breach of fiduciary duty to the company into a personal cause of action in tort. The only relevant question for the third party is whether the director was acting qua director. If the director was acting within the scope of their authority as the company's organ, the act is the company's act, and the director is immune.

The Two-Stage Test

The Court approved a two-stage test for determining a director’s liability, drawing on secondary literature by Tan Cheng Han (2011):

1. Did the director’s act create personal liability under the general law of tort (e.g., did they personally commit all elements of the tort)?
2. If so, does the Said v Butt principle nonetheless afford them immunity because they were acting as the company’s organ?

Applying this to the facts, the Court found that the Tannoses' decision to stop taking delivery of the chips was a decision made in their capacity as directors of Sandipala. There was no evidence that this decision was a breach of their duties to Sandipala. Even if the decision led to a breach of contract with Oxel, it was Sandipala’s breach, not a personal tort by the Tannoses.

Mitigation of Damages

Regarding Oxel’s counterclaim, the Court addressed the duty to mitigate. Sandipala argued that Oxel should have resold the 100 million chips to other buyers. The Court applied Section 17 of the Sale of Goods Act (Cap 393, 1999 Rev Ed), noting that property in the chips had not passed to Sandipala because they had not been paid for or delivered. However, the Court found that the chips were highly specialized (encoded with Oxel's proprietary PAC OS) and could not be easily resold in the open market. Therefore, Oxel had not failed in its duty to mitigate.

What Was the Outcome?

The Court of Appeal delivered a mixed result, though largely in favor of the respondents on the merits of the contractual dispute while vindicating the directors on the tortious claims. The operative conclusion of the Court was stated at [93]:

"In conclusion, we allow Sandipala and the Tannoses’ appeal only in relation to the claim in unlawful means conspiracy. We thus dismiss the entirety of Sandipala’s appeal against the first and third respondents (ST-AP and Mr Cousin) and the remainder of the appellants’ appeal against the second respondent (Oxel)."

The specific orders were as follows:

• Contractual Liability: The High Court’s finding that Sandipala breached the Supply Contract with Oxel was upheld. Sandipala remains liable for damages to be assessed.
• Conspiracy Claim: The finding of personal liability against Paulus Tannos and Catherine Tannos for unlawful means conspiracy was set aside. The conspiracy claim against Sandipala was also dismissed.
• Misrepresentation: All claims of fraudulent misrepresentation against ST-AP, Oxel, and Mr. Cousin were dismissed.
• Costs: The Court awarded Oxel net costs fixed at $35,000 inclusive of disbursements against Sandipala. The Court took into account that while Oxel succeeded on the contractual breach, it failed on the conspiracy claim which had occupied significant time in the High Court.
• Currency: The underlying transaction and damages were noted in US Dollars (USD), consistent with the Supply Contract.

Why Does This Case Matter?

This case is of paramount importance to the Singapore legal landscape for several reasons. First, it provides much-needed clarity on the Said v Butt principle. By shifting the focus away from a vague "best interests of the company" test to a more precise "breach of personal legal duties" test, the Court of Appeal has provided a clearer framework for both directors and practitioners. This ensures that directors can make difficult commercial decisions—including the decision to default on a contract—without the constant specter of personal tortious liability, provided they do not violate their duties to the company itself.

Second, the judgment reinforces the sanctity of the corporate veil in the context of tort law. It prevents the tort of conspiracy from being used as a "backdoor" to bypass the limitations of contract law. If a company breaches a contract, the remedy lies in contract against the company. Allowing a claimant to sue the directors for "conspiring" to cause that breach would effectively make directors personal guarantors of all corporate contracts, a result the Court found "odd" and commercially undesirable.

Third, the case highlights the high evidentiary burden required to prove conspiracy in a commercial setting. The Court of Appeal’s willingness to overturn the High Court’s factual finding on the directors' "predominant purpose" shows that appellate courts will scrutinize whether the alleged "injury" to the plaintiff was truly the goal of the directors, or merely an incidental consequence of a commercial decision intended to protect the company.

For practitioners, the case serves as a warning against over-pleading. Oxel’s decision to pursue a conspiracy claim against the directors, while ultimately unsuccessful on appeal, significantly complicated the litigation and impacted the final costs award. The Court’s analysis suggests that unless there is clear evidence of a director acting outside their corporate capacity or breaching fiduciary duties (e.g., siphoning funds), a conspiracy claim based on a corporate breach of contract is unlikely to succeed.

Finally, the decision aligns Singapore law with other major common law jurisdictions, including the UK and Australia, ensuring a consistent approach to directors' liability in international commerce. This stability is crucial for Singapore's status as a global commercial hub, where directors of multinational corporations require certainty regarding their legal exposure.

Practice Pointers

• Pleading Conspiracy: When acting for a plaintiff, avoid pleading unlawful means conspiracy against directors solely on the basis of the company’s breach of contract. To succeed, you must identify a breach of a personal legal duty owed by the director to the company.
• The "Bona Fide" Shield: For defense counsel, the Said v Butt immunity is a powerful tool. Emphasize that the director was acting qua director and that their actions, however detrimental to the third party, did not constitute a breach of duty to the company.
• Contractual Specificity: In supply contracts involving technical components, ensure that "evaluation chips" or "samples" are explicitly incorporated into the contract if they are intended to serve as the quality benchmark. Relying on "implied terms" or "identicality" is high-risk.
• Mitigation Evidence: In cases involving specialized goods, gather expert evidence early to demonstrate the lack of an alternative market. This is crucial to rebutting a "failure to mitigate" defense under the Sale of Goods Act.
• Director AEICs: When preparing Evidence-in-Chief for directors, focus on the commercial rationale for the company's actions to negate any finding of a "predominant purpose" to injure the counterparty.
• Costs Strategy: Be mindful that pursuing aggressive tort claims alongside contractual ones can lead to adverse costs consequences if the tort claims fail, even if the contractual claim succeeds.

Subsequent Treatment

Since its delivery, [2018] SGCA 17 has become the leading authority in Singapore for the proposition that directors enjoy a qualified immunity from tortious liability for their company's contractual breaches. It has been frequently cited in subsequent High Court decisions to strike out or dismiss conspiracy claims brought against company directors where the "unlawful means" alleged is merely the company's own breach of contract. The "two-stage test" and the refined "bona fide" requirement are now standard parts of the practitioner's toolkit in Singapore commercial litigation.

Legislation Referenced

• Sale of Goods Act (Cap 393, 1999 Rev Ed): Specifically Section 17, regarding the passing of property in goods based on the intention of the parties.
• Goods Act (Cap 393): Referenced in the context of the power of sale and contractual performance.

Cases Cited

• Applied:
  • Said v Butt [1920] 2 KB 497
• Referred to:
  • [2017] SGHC 102 (The High Court judgment under appeal)
  • [2018] SGHC 20 (Related High Court proceedings)
  • [2005] SGHC 98 (Otech Pakistan Pvt Ltd v Clough Engineering Ltd)
  • [2015] SGHC 206 (Tembusu Growth Fund Ltd v ACATek, Inc)
  • Chong Hon Kuan Ivan v Levy Maurice and others [2004] 4 SLR(R) 801
  • Nagase Singapore Pte Ltd v Ching Kai Huat and others [2008] 1 SLR(R) 80
  • M+W Singapore Pte Ltd v Leow Tet Sin and another [2015] 2 SLR 271
  • Ng Joo Soon v Dovechem Holdings Pte Ltd [2011] 2 SLR 1155
  • Vita Health Laboratories Pte Ltd and others v Pang Seng Meng [2004] 4 SLR(R) 162
  • Lim Leong Huat v Chip Hup Hup Kee Construction Pte Ltd [2009] 2 SLR(R) 318
  • Lim Leong Huat v Chip Hup Hup Kee Construction Pte Ltd [2011] 1 SLR 657
  • Chew Kong Huat and others v Ricwil (Singapore) Pte Ltd [1999] 3 SLR(R) 1167
  • Gabriel Peter & Partners v Wee Chong Jin and others [1997] 3 SLR(R) 649
  • TV Media Pte Ltd v De Cruz Andrea Heidi [2004] 3 SLR(R) 543
  • DC Thomson & Co Ltd v Deakin and others [1952] Ch 646
  • Sabaf SpA v MFI Furniture Centres Ltd [2002] EWCA Civ 976
  • O’Brien v Dawson (1942) 66 CLR 18

Source Documents

• Original Judgment on eLitigation
• Judgment PDF (CDN)